German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. - Wikidata - awgldk - TriplyDB

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

http://www.wikidata.org/entity/Q33436183

about

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Topics of nuclear medicine research in Europe.Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?Theranostics in nuclear medicine practice 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model.Labelling of 90Y- and 177Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis.Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.Saving costs in cancer patient management through molecular imaging.Lymph node imaging in initial staging of prostate cancer: An overview and update.Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Current status of theranostics in prostate cancer.Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.Update on radionuclide therapy in oncology.Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.It is time to move forward into the era of Theranostics.Radiotheranostics in Cancer Diagnosis and Management.Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].Advances in prostate-specific membrane antigen PET of prostate cancer.Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer?The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

P2860

Q33441176-F9CD1BC7-7E8B-4809-B0C8-85F7A6DB77D5 Q33581903-41A1135F-59B6-43F3-8743-3E4E702B85CD Q38720855-F781981E-280A-4BD3-9226-3CCE414A5A51 Q38821290-07A87B34-C13D-4D48-BA20-52E3853CFDE7 Q39458746-07997934-2F33-4633-B2E6-166434978E49 Q40208178-057DFC0C-8267-4CE1-905C-D26205F219B2 Q41192097-9597530A-DC32-498D-B2B8-C29D1DDCC06D Q41475179-948393FD-ED7E-49CF-B079-CD29B64DDF53 Q41549549-BD4674CF-08CF-4C75-829F-531F9AAABBB1 Q41856358-BB42CA33-7FC8-45AA-9032-94D2592C8464 Q42335930-68C53CC2-3526-4819-A52E-4C0CB3088B92 Q42373162-285DC67C-B605-4DDF-8146-8C6589474D45 Q42756624-50F66D90-C368-4D24-AA4A-289D63DE3539 Q43231046-33452EB8-2D07-4597-9D3E-0E10D438FD9F Q45753373-DB035CA9-2594-4864-A552-F23CDA93695F Q47107463-83B14DFC-5F0E-44FB-B539-B7226417EC73 Q47123424-85B77A1B-A748-4EF2-9D93-D6D4AD136096 Q47157403-FB0FDC78-00F8-4DC3-930A-4E9C91A65916 Q47158291-C3D2F992-669B-4F4D-8C48-925771773BF0 Q47241139-5D6DD53D-F19F-4E3D-8ED7-C98B0667D8BA Q47399023-3FE7E1C4-15BE-4BF2-94B9-167AA195C5F7 Q47552162-A241B8C8-FBE7-427F-9577-2403AA2E0040 Q47603267-29B042E8-5578-4EFC-88AC-8365AA309D3F Q47653267-4B6613B5-0EA4-49DB-9D80-FCB30C9D2B3D Q47705593-ACF8E19B-9DBB-4FB5-9D1E-CEA4F89CABA3 Q47719762-7642E3D2-128A-4292-8154-D711171E854E Q47731005-84165F5D-CAC6-4217-BCA4-D07608501A0E Q48107095-BA986624-94FB-41AC-9433-F4D215101C9E Q48127957-65F4D4AC-3F2F-4913-BB8F-B4448BC47E1F Q48194472-3BF97AD6-A015-4921-A2E4-9151F97AD5E7 Q48257941-A28AC324-F4EF-4C0F-BB78-35EC9985E530 Q48316505-6D619DBD-2EAD-4E33-9A4B-46FDD680D8BA Q49546570-E87FCA8A-4E6F-4FC4-B44F-57DCFCE99BA0 Q49713199-20207894-F281-4614-B7E3-7C2CC11CFB39 Q50084824-D1C69C0B-C4D9-45A4-B7FB-92EE1CA967D7 Q50087838-50EEF65D-C0B6-4673-AAC9-325B39712AA7 Q50777449-6A5FA503-EE84-45D9-9390-8ADAE6A108C1 Q52565554-20A794EB-06D1-4DD7-B61A-45DBA79CDF4D Q53695831-0F2E1081-A1BA-42B2-90A9-355E25C6FC25 Q54923034-2273AB49-4682-4650-86A9-C6B820ED7E0C

P2860

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

http://www.wikidata.org/entity/Q33436183

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@ast

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@en

type

label

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@ast

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@en

prefLabel

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@ast

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@en

P1433

Q33436183-469268D0-CCE9-4CB7-8B0E-870E316C2216

P1476

Q33436183-65A99FA5-9133-418E-B601-B44B77A7BA52

P2093

Q33436183-10E3361D-7C83-47AF-9199-92D84F4E5B95

Q33436183-16E114B3-4328-4EEA-B8CA-ECD4770AB79C

Q33436183-195F9C22-4A8E-48E8-B254-8B2B669DE003

Q33436183-22652FAC-52B1-4D03-B739-6B87892E5D5A

Q33436183-23BF5940-79E9-4E72-A1D0-83F1FF5798BC

Q33436183-39EC5C3F-4D35-4D0B-985B-DC51EAFF253E

Q33436183-44C17C1E-EFD5-45A8-9F5C-318F5A815845

Q33436183-58453839-9D6F-4A32-A7B7-7ACEA2E8F066

Q33436183-66A28851-94A6-4412-98A8-BA9AD43E7B98

Q33436183-6A25B8EA-B292-4EE0-ABF4-5D90147079E3

P304

Q33436183-C8A2B0D7-E4B2-413C-A328-B33C6B786F10

P31

Q33436183-280AEA4D-6BCB-4F2C-B051-89059E339B52

P356

Q33436183-B8E76FDC-AE0D-43BA-B106-E39EFC74E53A

P407

Q33436183-1E987DC2-1BE0-47C6-9F74-6C240CC0CC43

P433

Q33436183-6DF34935-6868-4557-A89E-BBC20BD54ACC

P478

Q33436183-D3B60FF0-83BD-482D-963C-F47BCD02882F

P50

Q33436183-36494333-3B33-48C6-A6B3-FE8258371264

Q33436183-963EB64A-65FF-4EF1-8622-91260B46FC48

P577

Q33436183-807B9146-1E54-45B7-BCBF-8D9114060DE7

P698

Q33436183-63C3FB83-37CA-4811-8228-E33BDC6B7A44

P921

Q33436183-61109040-DBEC-4FFA-976F-00F427E83A11

P356

JNUMED.116.183194

P1433

The Journal of Nuclear Medicine

P1476

German Multicenter Study Inves ...... nced Prostate Cancer Patients.

@en

P2093

Alexander Heinzel

http://www.w3.org/2001/XMLSchema#string

Andreas Pfestroff

http://www.w3.org/2001/XMLSchema#string

Bernd Joachim Krause

http://www.w3.org/2001/XMLSchema#string

Clemens Kratochwil

http://www.w3.org/2001/XMLSchema#string

Felix M Mottaghy

http://www.w3.org/2001/XMLSchema#string

Harshad R Kulkarni

http://www.w3.org/2001/XMLSchema#string

Hojjat Ahmadzadehfar

http://www.w3.org/2001/XMLSchema#string

Juri Ruf

http://www.w3.org/2001/XMLSchema#string

Kambiz Rahbar

http://www.w3.org/2001/XMLSchema#string

Markus Essler

http://www.w3.org/2001/XMLSchema#string

P304

85-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.116.183194

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Drzezga

P577

2016-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27765862

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial